Form 4: Omada Health CEO Sean Duffy Trades Shares

Omada Health CEO Sean P. Duffy reported transactions involving company stock, including purchases and sales executed under a 10b5-1 trading plan.

Summary

• Sean P. Duffy, Chief Executive Officer of Omada Health, Inc. (OMDA), engaged in several stock transactions on July 1, 2026.
• These transactions included the acquisition of 12,944 shares at $5.82 per share and 12,942 shares at $8.28 per share.
• Concurrently, Duffy disposed of 12,944 shares at a weighted average price of $22.6968 and 12,942 shares at a weighted average price of $22.6731.
• All sales were conducted under a Rule 10b5-1 trading plan adopted on March 13, 2026.
• Following these transactions, Duffy beneficially owns 424,805 shares directly and 851,659 shares indirectly through family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While there are both purchases and sales, the sales are executed under a pre-defined plan, and the purchases at lower prices could be seen as a positive signal, but the overall volume of sales balances this out.

Positives

• The CEO's stock purchases at lower prices ($5.82 and $8.28) could indicate a belief in future stock appreciation.
• The transactions were executed under a pre-arranged 10b5-1 plan, which is a standard and often positive corporate governance practice for insider trading.
• A significant number of shares (851,659) remain beneficially owned indirectly through family trusts, suggesting continued long-term commitment.

Negatives

• The disposal of a substantial number of shares at significantly higher prices ($22.6968 and $22.6731) compared to the purchase prices indicates a profit-taking strategy.
• The weighted average sale prices are considerably higher than the purchase prices, suggesting the CEO is realizing gains from previous appreciation.

Risks

• The sale of shares, even under a 10b5-1 plan, can sometimes be interpreted negatively by the market as a signal of reduced confidence by management, although the plan itself is designed to mitigate this.
• The significant difference between purchase and sale prices might suggest that the current market price is at a peak, potentially leading to future price declines if the company's performance does not sustain these levels.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions under the 10b5-1 plan are pre-determined and do not reflect current management outlook on future performance.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for public company insiders. The use of a 10b5-1 plan by Omada Health's CEO is a common practice to manage personal stock transactions in a way that avoids accusations of insider trading, especially during periods of significant stock price movement.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the sales as profit-taking by management, though the 10b5-1 plan mitigates concerns about insider trading. Purchases at lower prices could be seen as a positive signal.
• Employees: Similar to shareholders, the perception of management's confidence can influence morale.
• Creditors: No direct impact expected from this type of filing.

Next Steps

• Continued monitoring of Sean P. Duffy's beneficial ownership and any future transactions.
• Analysis of Omada Health's overall financial performance and strategic initiatives to contextualize insider trading activity.

Key Dates

Keywords

Omada Health, OMDA, Form 4, Insider Trading, Stock Transaction, 10b5-1 Plan, Sean P. Duffy, CEO, Beneficial Ownership, Stock Option